Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9692.7222
Address
Level 4 96-100 Albert Road South Melbourne, Victoria (VIC) 3205
Description
PharmAust Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. It operates under the Corporate and Research, and Pharmaceutical-Epichem segments. The Corporate and Research segment includes corporate overhead expenses. The Pharmaceutical-Epichem segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company was founded on December 2003 and is headquartered in Claremont, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.07 - 0.54
Trade Value (12mth)
AU$49,984.00
1 week
-7.14%
1 month
-4.88%
YTD
77.27%
1 year
143.75%
All time high
4.74
EPS 3 yr Growth
321.700%
EBITDA Margin
-116.70%
Operating Cashflow
-$2m
Free Cash Flow Return
-22.90%
ROIC
-90.90%
Interest Coverage
-40.30
Quick Ratio
2.20
Shares on Issue (Fully Dilluted)
354m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
25 July 24 |
Application for quotation of securities - PAA
×
Application for quotation of securities - PAA |
24 July 24 |
PharmAust Completes Share Purchase Plan
×
PharmAust Completes Share Purchase Plan |
15 July 24 |
Monepantel Selected for Entry into HEALEY ALS Platform Trial
×
Monepantel Selected for Entry into HEALEY ALS Platform Trial |
15 July 24 |
Investor Update - HEALEY ALS Platform Trial Selection
×
Investor Update - HEALEY ALS Platform Trial Selection |
08 July 24 |
Investor Briefings & Webinar Notice
×
Investor Briefings & Webinar Notice |
01 July 24 |
PharmAust Granted SME Status by European Medicines Agency
×
PharmAust Granted SME Status by European Medicines Agency |
28 June 24 |
Share Purchase Plan Cleansing Notice
×
Share Purchase Plan Cleansing Notice |
28 June 24 |
Share Purchase Plan Offer Booklet
×
Share Purchase Plan Offer Booklet |
28 June 24 |
Application for quotation of securities - PAA
×
Application for quotation of securities - PAA |
28 June 24 |
Application for quotation of securities - PAA
×
Application for quotation of securities - PAA |
28 June 24 |
Notification regarding unquoted securities - PAA
×
Notification regarding unquoted securities - PAA |
28 June 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
27 June 24 |
Application for quotation of securities - PAA
×
Application for quotation of securities - PAA |
21 June 24 |
PharmAust raises $10 million via Placement and announces SPP
×
PharmAust raises $10 million via Placement and announces SPP |
21 June 24 |
Proposed issue of securities - PAA
×
Proposed issue of securities - PAA |
21 June 24 |
PharmAust Presentation
×
PharmAust Presentation |
19 June 24 |
Trading Halt
×
Trading Halt |
19 June 24 |
Initial Director's Interest Notice - K.MacFarlane
×
Initial Director's Interest Notice - K.MacFarlane |
18 June 24 |
PharmAust's Phase 1 Study Data Presented at Major Conference
×
PharmAust's Phase 1 Study Data Presented at Major Conference |
17 June 24 |
Appointment of Non-Executive Director
×
Appointment of Non-Executive Director |
05 June 24 |
OLE Study update reveals impressive Survival Data
×
OLE Study update reveals impressive Survival Data |
04 June 24 |
Final Director's Interest Notice - J.Clark
×
Final Director's Interest Notice - J.Clark |
04 June 24 |
Initial Director's Interest Notice - M.Thurn
×
Initial Director's Interest Notice - M.Thurn |
31 May 24 |
Executive team strengthened, appointment of MD/CEO & new CSO
×
Executive team strengthened, appointment of MD/CEO & new CSO |
28 May 24 |
Change of Registered Office and Principal Place of Business
×
Change of Registered Office and Principal Place of Business |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.